Thyroid Replacement (T4) Class Overview Monograph

Mechanism of Action and Pharmacology

Levothyroxine provides exogenous thyroxine (T4) that the body converts to the biologically active triiodothyronine (T3) through selenium-dependent deiodinase enzymes in peripheral tissues including the liver, kidneys, and skeletal muscle [1]. This pro-hormone strategy mirrors normal thyroid physiology, where roughly 80% of circulating T3 originates from peripheral deiodination rather than direct thyroidal secretion.

Receptor Binding and Genomic Effects

T3 binds nuclear thyroid hormone receptors (TR-alpha and TR-beta), forming heterodimers with retinoid X receptors that modulate transcription of over 200 target genes [2]. TR-beta predominates in the liver, kidney, and pituitary, mediating TSH feedback suppression and hepatic lipid metabolism. TR-alpha predominates in the heart, bone, and CNS, explaining the cardiovascular sensitivity to both excess and deficiency.

Peripheral Conversion Physiology

Type 2 deiodinase (D2) in the CNS and pituitary converts T4 to T3 locally, maintaining brain T3 levels even when serum T3 is low-normal. Type 3 deiodinase (D3) inactivates T4 to reverse T3 (rT3), serving as a protective brake during critical illness. Polymorphisms in the DIO2 gene (Thr92Ala variant, present in roughly 16% of White populations) may alter intracellular T3 generation, though the 2014 ATA guidelines note that "evidence remains insufficient to recommend genotyping to guide therapy" [3].

Pharmacokinetics Across Formulations

The T4 class includes tablets, soft-gel capsules, and oral solutions. These are not interchangeable. Bioavailability differences between formulations can shift TSH by 30% or more, making formulation consistency a prescribing priority [4].

Tablet Formulations

Standard levothyroxine tablets (Synthroid, Levoxyl, Unithroid) have bioavailability ranging from 40% to 80%, heavily influenced by gastric pH and concurrent food intake. The FDA's 2004 Guidance for Industry mandated that levothyroxine products demonstrate bioequivalence within a tightened AUC window of 90-111%, down from the standard 80-125% [5]. Fasting absorption is optimal; a 2017 study in Thyroid (N=45) showed that taking levothyroxine 60 minutes before breakfast yielded TSH values 1.06 mIU/L lower on average compared to 30 minutes pre-meal [6].

Soft-Gel Capsule (Tirosint)

Tirosint eliminates traditional excipients (no dyes, gluten, lactose, sugar). Its gel matrix dissolves independently of gastric pH, producing bioavailability near 98% [4]. In a crossover trial published in Endocrine Practice (N=34), patients with documented malabsorption on tablet levothyroxine achieved TSH normalization within 8 weeks of switching to the same microgram dose of Tirosint without dose escalation [7].

Oral Solution (Tirosint-SOL)

The liquid formulation provides absorption equivalent to the soft-gel capsule and is particularly useful for patients receiving concurrent PPI therapy or those with swallowing difficulties. A 2021 study in the Journal of the Endocrine Society demonstrated that liquid levothyroxine maintained stable TSH in 87% of patients co-administered omeprazole, compared with 63% on tablet formulation [8].

Dosing Algorithms

Full replacement dosing in otherwise healthy adults follows a weight-based calculation of 1.6 mcg/kg/day of ideal body weight. Actual starting doses depend on age, cardiac status, and the severity of hypothyroidism [3].

Young, Healthy Adults

For patients under 50 without cardiovascular disease, clinicians can initiate full replacement immediately. A 70 kg adult would start at approximately 112 mcg daily, rounded to the nearest available tablet strength (e.g., 112 mcg or 100 mcg). TSH should be rechecked at 6-8 weeks [3].

Older Adults and Cardiac Patients

The ATA recommends starting at 25-50 mcg daily in patients over 50 or those with known coronary artery disease, with dose increases of 12.5-25 mcg every 6-8 weeks [3]. Aggressive initial dosing in this population risks atrial fibrillation and angina. A population-based Danish cohort (N=628,953) found that patients aged 65+ initiated on levothyroxine doses above 75 mcg had a 1.37-fold higher rate of atrial fibrillation within 90 days compared to those started below 50 mcg [9].

TSH-Based Titration

The 2014 ATA guidelines define target TSH as the laboratory-specific reference range, generally 0.4-4.0 mIU/L, while noting that most treated patients feel best with TSH between 0.5 and 2.5 mIU/L [3]. Over-suppression below 0.1 mIU/L carries documented risks: a meta-analysis in JAMA Internal Medicine (N=70,298 pooled) associated subclinical hyperthyroidism with a 1.68-fold increased risk of hip fracture in postmenopausal women [10].

Drug Interactions and Absorption Interference

T4 has a narrow therapeutic index. Interactions that reduce absorption by even 15-20% can produce clinically meaningful TSH elevation. The 2014 ATA guidelines state that "medications or supplements that interfere with levothyroxine absorption should be separated by at least 4 hours" [3].

Cation-Containing Compounds

Calcium carbonate, ferrous sulfate, and aluminum-containing antacids chelate levothyroxine in the GI lumen. A pharmacokinetic study in Thyroid showed that simultaneous calcium carbonate administration reduced levothyroxine AUC by 25% [11]. Iron sulfate has a similar magnitude of effect. Separation by 4 hours restores full absorption.

Proton Pump Inhibitors

PPIs raise gastric pH, impairing dissolution of levothyroxine tablets (which require acidic conditions for disintegration). A retrospective analysis of 137 patients on stable levothyroxine found that adding a PPI increased mean TSH by 1.71 mIU/L within 3 months [12]. Switching to a pH-independent formulation (Tirosint or liquid) is preferable to empiric dose escalation.

Bile Acid Sequestrants and Enzyme Inducers

Cholestyramine and colesevelam bind levothyroxine in the gut and should be taken 4-6 hours apart. Hepatic enzyme inducers (rifampin, phenytoin, carbamazepine, phenobarbital) accelerate T4 clearance through CYP3A4 and UGT induction, frequently requiring a 20-30% dose increase during co-administration [13].

Biotin Interference with Assays

High-dose biotin (5-10 mg daily, commonly marketed for hair and nails) does not interact with the drug itself but produces analytical interference with streptavidin-biotin immunoassays, yielding falsely low TSH and falsely high free T4. The Endocrine Society recommends discontinuing biotin 48-72 hours before thyroid function testing [14].

Monitoring Parameters

Effective monitoring extends beyond TSH alone. A systematic approach reduces both under-treatment and iatrogenic thyrotoxicosis.

Baseline and Follow-Up Labs

Before initiation: TSH, free T4, thyroid peroxidase antibodies (TPO-Ab). TPO-Ab positivity predicts progression from subclinical to overt hypothyroidism at a rate of roughly 4.3% per year, per the Whickham Survey follow-up data [15]. After dose initiation or any change: recheck TSH at 6-8 weeks. Once stable, annual TSH is sufficient for most patients.

When to Check Free T4

Free T4 measurement is unnecessary in routine primary hypothyroidism monitoring when TSH is reliable. It becomes essential in central (secondary) hypothyroidism, where TSH is an unreliable marker because the pituitary itself is dysfunctional. Target free T4 in the upper half of the reference range in these patients [3].

Bone Density Considerations

Postmenopausal women on suppressive-dose levothyroxine (TSH <0.1 mIU/L) should have baseline DEXA and repeat scanning per ISCD guidelines. The American Association of Clinical Endocrinologists states that "TSH suppression therapy should target the lowest effective level of suppression, balancing recurrence risk against skeletal and cardiovascular harm" [16].

Special Populations

Pregnancy

Thyroid hormone requirements increase by 25-50% as early as week 4-6 of gestation due to rising hCG-mediated thyroid stimulation and estrogen-induced TBG elevation [17]. The 2017 ATA Pregnancy Guidelines recommend that women on levothyroxine increase their dose by approximately 30% upon confirmation of pregnancy (a practical rule: take two extra doses per week) and check TSH every 4 weeks through mid-gestation [17]. Trimester-specific TSH targets apply: first trimester upper limit of 4.0 mIU/L using population-based reference ranges, or 0.5 mIU/L below the non-pregnant upper limit if lab-specific ranges are unavailable.

Elderly Patients

In adults over 70, the TSH set point shifts upward physiologically. Data from NHANES III showed that the 97.5th percentile of TSH in disease-free adults aged 70-79 was 5.9 mIU/L, compared with 4.1 mIU/L in adults aged 20-29 [18]. Over-treatment of mildly elevated TSH (4.5-10 mIU/L) in the elderly has not demonstrated symptom benefit. The TRUST trial (N=737, mean age 74.4 years) found no improvement in hypothyroid symptoms or tiredness scores after 12 months of levothyroxine versus placebo in older adults with subclinical hypothyroidism [19].

Malabsorptive Conditions

Celiac disease, inflammatory bowel disease, prior bariatric surgery, and chronic PPI use all impair levothyroxine tablet absorption. Switching to liquid or soft-gel formulation before dose escalation prevents unnecessary supratherapeutic dosing. Post-Roux-en-Y gastric bypass patients commonly require 20-50% higher doses or a formulation change [20].

Myxedema Coma

This life-threatening decompensation of severe hypothyroidism requires IV levothyroxine loading: 200-400 mcg IV bolus followed by 1.6 mcg/kg/day IV (reduced by 25% in elderly or cardiac patients), with concurrent IV hydrocortisone 100 mg every 8 hours until adrenal insufficiency is excluded [21]. Mortality remains 30-60% even with treatment, underscoring the importance of early recognition.

Thyroid Cancer TSH Suppression

In differentiated thyroid cancer (DTC), levothyroxine serves a dual role: hormone replacement and TSH suppression to reduce recurrence. The 2015 ATA DTC guidelines stratify suppression targets by risk [22].

Risk-Stratified Targets

High-risk patients (gross extrathyroidal extension, incomplete tumor resection, distant metastases): target TSH <0.1 mIU/L. Intermediate-risk patients: target TSH 0.1-0.5 mIU/L. Low-risk patients with excellent response to therapy: target TSH 0.5-2.0 mIU/L, effectively identical to the general hypothyroidism range [22]. Dr. Bryan Haugen, lead author of the 2015 ATA guidelines, emphasized that "the era of lifelong TSH suppression below 0.1 for all thyroid cancer patients is over; risk stratification should guide the degree of suppression" [22].

Long-Term Surveillance

After initial suppression, dynamic risk restratification using stimulated thyroglobulin and neck ultrasonography determines whether suppression intensity can be relaxed. Most low-risk patients can be moved to physiologic replacement (TSH 0.5-2.0 mIU/L) within 1-2 years if thyroglobulin remains undetectable [22].

Adverse Effects and Over-Treatment

Levothyroxine is well tolerated at physiologic doses. Nearly all adverse effects reflect excess dosing (iatrogenic thyrotoxicosis) rather than drug-specific toxicity.

Cardiovascular

Supraphysiologic T4 increases heart rate, myocardial oxygen demand, and atrial ectopy. A UK primary care database study (N=17,684) found that patients with TSH persistently below 0.03 mIU/L had a hazard ratio of 1.6 for new-onset atrial fibrillation over 7 years [23].

Skeletal

Chronic TSH suppression accelerates bone turnover. Postmenopausal women are at greatest risk. The effect is dose-dependent: mild suppression (TSH 0.1-0.4 mIU/L) has minimal skeletal impact, while sustained TSH <0.1 mIU/L reduces BMD by 1-2% per year at the femoral neck [10].

Pseudo-Malabsorption

Persistent TSH elevation despite escalating doses (sometimes exceeding 300-400 mcg daily) most commonly reflects non-adherence rather than true malabsorption. A supervised ingestion test (witnessed administration of the weekly dose with TSH and free T4 measured at 0, 2, and 4 hours) differentiates the two causes [24].

Generic Substitution and Formulation Switching

The narrow therapeutic index of levothyroxine makes unmonitored generic substitution a clinical concern. The ATA, AACE, and The Endocrine Society issued a joint statement recommending that "patients should be maintained on a consistent levothyroxine preparation and, when switching is necessary, TSH should be retested in 6 weeks" [25]. Pharmacy-level generic substitution without prescriber notification remains common. Writing "dispense as written" or specifying the brand or manufacturer can prevent unintended switching in patients on stable, optimized regimens.